C-Further is a joint initiative of three of the UK’s most influential non-profit organisations, Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity, created to tackle one of the most underserved areas of oncology: children and young people’s cancers.
This recent Financial Times piece, which opens with one father’s experience of losing his son to a brain tumour, shows why this matters.
Progress in paediatric oncology has stalled for two decades because the commercial incentive to develop dedicated therapeutics is weak. With £37m of initial backing, C-Further is stepping in to absorb the early risk that commercial investors cannot, illustrating what mission-driven capital can make possible: translation that would otherwise not happen.
Read the article on the Financial Times
